An investigational antibody demonstrated an ability to preserve vision in people with geographic atrophy from dry age-related ...

Age-related macular degeneration (AMD) is one of the leading causes of vision ... Since AMD is closely linked with aging, some researchers have turned their attention to metformin—a drug better known ...

According to a study presented at the American Academy of Ophthalmology’s annual meeting in Chicago, investigational ...

Researchers led by the University Hospital Zurich have identified cases of sterile intraocular inflammation, including severe retinal vasculitis, associated with faricimab injections used to treat eye ...

Light therapy could be a useful treatment for the most common form of age-related macular degeneration, a new study says.

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a ...

The ELEVATUM study's initial data showed vision improvements in patients who were given Vabysmo every eight weeks for a year.

Novo Nordisk asked the FDA to bar compounding pharmacies from making semaglutide, arguing it is too complex for the ...

Data about higher doses that are injected less often come as the original 2-milligram dose of Eylea is facing an increasing ...

The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic ...